Polyclonal Antibodies Market To Reach $2.21 Billion By 2030

Polyclonal Antibodies Market Growth & Trends 

The global polyclonal antibodies market size is anticipated to reach USD 2.21 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.01% from 2023 to 2030. The increasing technological advancements in the production of antibodies-based drugs, the growing prevalence of infectious & chronic diseases such as cancer across the globe, and the rising number of biopharmaceutical research and development activities are the main drivers of the industry. In addition, Polyclonal antibodies (pAbs) are extensively utilized in both quantitative and qualitative biological research as well as several diagnostic tests.

The use of polyclonal antibodies has had a positive impact on the treatment of COVID-19 patients, with studies showing that these therapies can reduce hospitalization rates and improve outcomes for patients with mild to moderate disease. Additionally, the development of pAbs has helped to advance the understanding of the immune response to COVID-19 and is projected to lead the development of more effective treatments and vaccines in the future. Thus, the COVID-19 pandemic has had a significant impact on the pAbs market.

Several government initiatives support and promote the development and use of polyclonal antibodies in various applications, including diagnostics, therapeutics, and research. These initiatives are aimed at improving healthcare outcomes, promoting innovation, and supporting the growth of the biotechnology and pharmaceutical industries. Moreover, many governments are also taking initiatives to promote collaborations between academic institutions, research organizations, and industry players in the pAbs market. For instance, in May 2020, the Canadian Government invested USD 175 million in AbCellera, to support the organization in its antibody treatment examination and the production of the antibody construction facility. Thus, such various government initiatives are anticipated to increase the demand for the pAbs market.

 Request a free sample copy or view report summary: Polyclonal Antibodies Market Report

Polyclonal Antibodies Market Report Highlights

• Based on the product, the secondary antibodies segment dominated in terms of the revenue share of 56.14% in 2022, owing to the high sensitivity and enhanced signal amplification quality, thus increasing the demand in the industry

• Based on end-user, the hospital & diagnostic centers segment dominates in terms of the revenue share of 59.81% in 2022. This is attributed to the increasing demand for pAbs-based assays in diagnostic centers and the rising prevalence of chronic & infectious diseases

• Based on application, the diagnostics segment dominated in terms of the revenue share of 59.81% in 2022. Due to the ability of pAbs to recognize the epitopes of targeted molecules, it is regarded as the optimum reagent in hemagglutination assays and diagnostics. Thus, increasing the demand for diagnostics in the application segment

• Based on source, the rabbit segment dominated in terms of the revenue share of 50.69% in 2022. Abs from rabbits have a high level of specificity and can bind to a variety of proteins at picomolar concentrations. Hence, the demand for rabbit-based Abs is expected to increase in the future

• In 2022, North America dominated with a revenue share of over 38.62%, due to various factors, such as advancements in technology and healthcare infrastructure. The presence of a large number of biotechnology and pharmaceutical industry players is anticipated to increase the overall research and development of various antibody-based drugs, resulting in market growth

• Asia Pacific accounted for the fastest-growing region with a CAGR of 9.67% during the forecast period. The increasing prevalence of chronic diseases and rising demand for personalized medicine are expected to fuel the upsurge in the market

Polyclonal Antibodies Market Segmentation

Grand View Research has segmented the global polyclonal antibodies market based on product, application, source, end-user, and region: 

Polyclonal Antibodies (pAbs) Product Outlook (Revenue, USD Million, 2018 - 2030)

• Primary Antibodies

• Secondary Antibodies

Polyclonal Antibodies (pAbs) Application Outlook (Revenue, USD Million, 2018 - 2030)

• Biomedical Research

• Diagnostics

Polyclonal Antibodies (pAbs) Source Outlook (Revenue, USD Million, 2018 - 2030)

• Rabbits

• Goats

• Sheep

• Mouse

• Others

Polyclonal Antibodies (pAbs) End-User Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical & Biotechnology Companies

• Hospitals & Diagnostic Centers

• Academic & Research Center

Polyclonal Antibodies (pAbs) Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of key players in the Polyclonal Antibodies (pAbs) Market

• Thermo Fisher Scientific Inc. 

• Merck KGaA

• Abcam plc.

• ProteoGenix

• Proteintech Group, Inc. 

• Bio-Rad Laboratories Inc.

• BPS Bioscience, Inc.

• R&D Systems, Inc. 

• Agilent Technologies, Inc.

• Atlas Antibodies

• CUSABIO TECHNOLOGY LLC 

• ROCKLAND IMMUNOCHEMICALS, INC.